

REMARKS

By the present Amendment, Claims 1-9 are pending. Claims 1-6 are original. Claims 7-9 are withdrawn. Support for the amendments may be found in the specification, including for example in the original claims and sequence listing. No new matter is added by way of these amendments.

In the Restriction Requirement dated January 12, 2011 ("Restriction Requirement"), the Examiner required Applicants to elect a single group for examination from among the following five groups:

Group I, claims 1-6, drawn to a method of neuroprotection comprising administering to a stroke patient an AMPK inhibitor.

Group II, claim 7, drawn to a pharmaceutical composition comprising C75.

Group III, claim 7, drawn to a pharmaceutical composition comprising Compound C.

Group IV, claim 8, drawn to a pharmaceutical composition comprising an AMPK direct inhibitor.

Group V, claim 9, drawn to a pharmaceutical composition comprising an AMPK indirect inhibitor.

Restriction Requirement at page 2.

Applicants provisionally elect, with traverse, Group I, characterized by the Examiner as being "drawn to a method of neuroprotection comprising administering to a stroke patient an AMPK inhibitor". Applicants respectfully submit that claims 1-6 read on the elected group.

Applicants expressly reserve the right to rejoin non-elected species upon allowance of claims to the presently elected species.

Applicants submit that complete examination of the captioned application would be handled most expeditiously by treating all of the pending claims as a single entity. As M.P.E.P. § 803 directs, "[i]f the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to independent or distinct inventions." Indeed, Applicants respectfully submit that the Examiner

has not shown that a search of the entire application would cause a serious burden. Rather, a serious burden would arise if the application were restricted.

CONCLUSION

In view of the foregoing amendments and remarks, Applicants submit that the present application is now in condition for allowance and respectfully request notice of such. The Examiner is encouraged to contact the undersigned at 202-942-5325 if any additional information is necessary for allowance.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Lisa A. Adelson". The signature is fluid and cursive, with the first name "Lisa" and last name "Adelson" clearly distinguishable.

David R. Marsh (Reg. No. 41,408)
Lisa A. Adelson (Reg. No. 51,204)

Date: April 12, 2011

ARNOLD & PORTER LLP
Attn: IP Docketing
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile